Yes, TAMs are considered promising targets for cancer therapy. Several strategies are being explored to modulate the activity or presence of TAMs in the tumor microenvironment. These include reprogramming TAMs from a pro-tumorigenic (M2) to an anti-tumorigenic (M1) phenotype, inhibiting their recruitment to the tumor site, and depleting them altogether. For example, CSF-1R inhibitors can reduce the number of TAMs in the tumor microenvironment, potentially slowing down tumor progression.
